Myriad Decision Made

Aug 01, 2011

A federal appeals court has ruled that genes can be patented, and upheld Myriad Genetics' patents for the BRCA1 and BRCA2 genes, reports The New York Times' Andrew Pollack. Myriad uses the genes as the basis for its BRCAnalysis diagnostic test to detect mutations in the BRCA genes. In March 2010, New York Southern District Court Judge Robert Sweet invalidated the patents and said that genes can't be patented because they are products of nature.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Billion-Pound Sticking Point

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

Advisors Push for More Data

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

Moderna Expects Early Trial Data Next Month

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

Science Papers Explore Contribution of ANXA11 to ALS, Role of Gut Microbiome in Autism Spectrum Disorder

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.

Menu